Application of Modern Methods of Dietotherapy and Nutriceutics in the Treatment of Dyslipidemia (Literature Review)
DOI:
https://doi.org/10.51699/ijhsms.v2i12.3135Keywords:
dyslipidemia, overweight, obesity, nutraceuticals, vegetarian dietAbstract
All patients with dyslipidemia should be advised to reduce their intake of saturated fats due to their adverse effect on the risk of cardiovascular events due to their proatherogenic effect. Regardless of the disease, it is necessary to exclude Tran’s fatty acids due to an increased risk of developing premature atherosclerosis.
In the presence of overweight and obesity, it is necessary to limit the total calorie content of the diet (up to 2,000 kkal / day) to normalize body weight and reduce cardiovascular risk. In the group of patients with moderate and low risk of CVD, the use of special nutraceutical agents and functional foods that affect the lipid spectrum may be promising, but requires further rese.
Downloads
References
Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal. 2016; 37(39):2999– 3058. DOI: 10.1093/eurheartj/ehw272
Banach M, Jankowski P, Jóźwiak J, Cybulska B, Windak A, Guzik T et al. PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016. Archives of Medical Science. 2017; 13(1):1–45. DOI: 10.5114/aoms.2017.64712
Boytsov S. A., Pogosova N. V., Bubnova M. G., Drapkina O. M., Gavrilova N. E., Yeganyan R. A. et al. Cardiovascular prevention 2017. National guidelines. Russian Journal of Cardiology. 2018; 23 (6):7–122. [Russian: Бойцов С. А., Погосова Н. В., Бубнова М. Г., Драпкина О. М., Гаврилова Н. Е., Еганян Р. А. и др. Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский кардиологический журнал. 2018;23(6):7–122]. DOI: 10.15829/1560-4071-2018-6-7-122
Ezhov M. V., Sergienko I. V., Aronov D. M., Arabidze G. G., Akhmedzhanov N. M., Bazhan S. S. et al. Diagnostics and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis. Russian recommendations VI revision. Atherosclerosis and Dyslipidemias. 2017;3:5–22. [Russian: Ежов М. В., Сергиенко И. В., Аронов Д. М., Арабидзе Г. Г., Ахмеджанов Н. М., Бажан С. С. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VI пересмотр. Атеросклероз и дислипидемии. 2017;3:5-22]
Wolfram G, Bechthold A, Boeing H, Ellinger S, Hauner H, Kroke A et al. Evidence-Based Guideline of the German Nutrition Society: Fat Intake and Prevention of Selected Nutrition-Related Diseases. Annals of Nutrition and Metabolism. 2015;67(3):141–204. DOI: 10.1159/000437243
Жўраева Х. и др. Артериал гипертензия ва метаболик синдром //Вoshqaruv va etika qoidalari onlayn ilmiy jurnali. – 2021. – Т. 1. – №. 6. – С. 106-111.
Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of LDLlowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials. Lancet, 2015, 385(9976): 1397–1405.
Sahebkar A, Serban MC, Gluba-Brzózka A et al. Lipid-modifying effects of nutraceuticals: An evidence-based approach. Nutrition, 2016, 32: 1179–92.
Джураева Х.И. и др. Профилактика основных компонентов метаболиче –ского синдрома. – 2019.
Amir Shaghaghi M, Abumweis SS, Jones PJ. Cholesterol-lowering efficacy of plant sterols/ stanols provided in capsule and tablet formats: results of a systematic review and meta-analysis. J Acad Nutr Diet, 2013, 113: 1494–503.
Ras RT, Geleijnse JM, Trautwein EA. LDL cholesterol-lowering effect of plant sterols and stanols across different dose ranges: A metaanalysis of randomised controlled studies. Br J Nutr, 2014, 112: 214–9.
Han S, Jiao J, Xu J et al. Effects of plant stanol or sterol-enriched diets on lipid profiles in patients treated with statins: systematic review and meta-analysis. Sci Rep, 2016, 6: 31337.
Ras RT, van der Schouw YT, Trautwein EA et al. Intake of phytosterols from natural sources and risk of cardiovascular disease in the European prospective investigation into cancer and nutrition- the Netherlands (EPIC-NL) population. Eur J Prev Cardiol, 2015, 22: 1067–75.
Yubero N, Sanz-Buenhombre M, Guadarrama A et al. LDL cholesterol-lowering effects of grape extract used as a dietary supplement on healthy volunteers. Int J Food Sci Nutr, 2013, 64: 400–6.
Sahebkar A, Serban C, Ursoniu S et al. Lipid and Blood Pressure Meta-analysis Collaboration Group. Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors–Results from a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol, 2015, 189: 47–55.
Sansone R, Rodriguez-Mateos A, Heuel J et al. Cocoa flavanol intake improves endothelial function and Framingham Risk Score in healthy men and women: a randomized, controlled, double-masked trial: the Flaviola Health Study. Br J Nutr, 2015, 114: 1246–55.5.
Hartley L, Flowers N, Holmes J et al. Green and black tea for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev, 2013, 18: CD009934.
Zhao Y, Asimi S, Wu K et al. Black tea consumption and serum cholesterol concentration: Systematic review and meta-analysis of randomized controlled trials. Clin Nutr, 2015, 34: 612–9.
Khafiza, J. ., & Dildora, T. . (2023). Frequency of Comorbid Pathology among Non-Organized Population. Research Journal of Trauma and Disability Studies, 2(4), 260–266.Retrieved from http://journals.academiczone.net/index.php/rjtds/article/view/753
Serban MC, Sahebkar A, Dragan S et al. A systematic review and meta-analysis of the impact of Spirulina supplementation on plasma lipid concentrations. Clin Nutr, 2016, 35: 842–51.
Stone NG, Robinson JG, Lichtenstein AH et al. ACC/AHA Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol, 2014, 63(25 pt B): 2889–2934.
Collins R, Reith C, Emberson J et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet, 2016, 388
